FDA staff says BiDil cuts deaths among black heart patients

06/16/2005 | Reuters

An FDA staff analysis says NitroMed's heart-failure drug BiDil significantly reduced deaths and hospitalizations among blacks in a clinical study, and it should be indicated for treatment of black patients. The staff report was released in advance of today's FDA advisory panel meeting to decide if BiDil should become the first drug approved for treatment of a specific racial group.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI